08:00 , Nov 9, 2015 |  BC Week In Review  |  Company News

Stanford University, Abeona Therapeutics deal

Stanford granted Abeona a license to an adeno-associated virus (AAV) delivery vector to treat Fanconi anemia. Abeona said the license augments a June deal with the University of Minnesota granting the company rights to ABO-301...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Company News

University of Minnesota, Abeona Therapeutics deal

The university granted Abeona exclusive, worldwide rights to CRISPR- Cas9 gene editing technology and related IP to develop products for non-cancer indications, including rare blood disorders. Abeona’s lead product using the technology is ABO-301 ,...